

What Is Claimed Is:

1. A method for diagnosing spontaneous abortion, comprising providing contact between a sample of body fluid and an antigen capable of binding to an antibody to platelet activating factor (PAF), and assessing the presence and/or  
5 concentration of antibodies to PAF and/of of antibodies to an antigen capable of binding to antibodies to PAF in the sample of body fluid.

2. The method of claim 1 comprising measuring the  
10 presence and/or concentration of antibodies to PAF and/or of antibodies to an antigen capable of binding to antibodies to PAF by immunoassay.

3. The method of claim 1 comprising measuring the presence and/or concentration of antibodies to PAF and/or of  
15 antibodies to an antigen capable of binding to antibodies to PAF by an enzyme linked immunosorbent assay.

4. The method of claim 1 comprising measuring the presence and/or concentration of antibodies to PAF and/or of  
20 antibodies to an antigen capable of binding to antibodies to PAF by radioimmunoassay.

5. The method of claim 1 comprising measuring the presence and/or concentration of antibodies to PAF and/or of

antibodies to an antigen capable of binding to antibodies to PAF in serum prepared from a blood sample.

6. The method of claim 1 comprising measuring the presence and/or concentration of antibodies to PAF and/or of  
5 antibodies to an antigen capable of binding to antibodies to PAF in plasma prepared from a blood sample.

7. The method of claim 1 wherein said sample of body fluid is a human blood sample or fraction thereof, and the measuring of antibodies to PAF and/or of antibodies  
10 capable of binding to antibodies to PAF is by immunoassay.

8. The method of claim 1 wherein said antigen capable of binding to antibodies to PAF is phosphocholine.

9. The method of claim 1 wherein said antigen capable of binding to antibodies to PAF is phosphorylcholine.

15 10. The method of claim 1 wherein said antigen capable of binding to antibodies to PAF is phosphatidylcholine.

11. The method of claim 1 wherein said antigen capable of binding to antibodies to PAF is  
20 lysophosphatidylcholine.

12. A kit for carrying out the method according to claim 1, said kit comprising means for testing the presence and/or concentration of antibodies to PAF and/of of antibodies to an antigen capable of binding to antibodies to PAF in a sample of body fluid of a patient to be tested for spontaneous abortion; and means for determining from the assayed concentration of either or both of said antibodies whether or not the patient is at risk for having spontaneous abortion.

13. A kit for diagnosing spontaneous abortion that utilizes several diagnostic indicators for spontaneous abortion, wherein antibodies to PAF and/or of antibodies to an antigen capable of binding to antibodies to PAF is one of them.

14. The kit of claim 12 wherein said means for testing the presence and/or the concentration of antibodies to PAF and/or of antibodies to an antigen capable of binding to antibodies to PAF comprises measuring either or both of said antibodies by immunoassay.

15. The kit of claim 12 wherein said means for testing the presence and/or the concentration of antibodies to PAF and/or of antibodies to an antigen capable of binding to antibodies to PAF comprises measuring either or both of said antibodies by an enzyme linked immunosorbent assay.

16. The kit of claim 12 wherein said means for testing the presence and/or the concentration of antibodies to PAF and/or of antibodies to an antigen capable of binding to antibodies to PAF comprises measuring either or both of said  
5 antibodies by radioimmunoassay.

17. The kit of claim 12 wherein said sample of body fluid is serum prepared from a blood sample.

18. The kit of claim 12 wherein said sample of body fluid is plasma prepared from a blood sample.

10 19. The kit of claim 12 wherein said sample of body fluid is a human blood sample or fraction thereof, and said means for testing the presence and/or the concentration of antibodies to PAF and/or of antibodies to an antigen capable of binding to antibodies to PAF comprises measuring either or  
15 both of said antibodies by immunoassay.

20. The kit of claim 12 wherein said antigen capable of binding to antibodies to PAF is phosphocholine.

21. The kit of claim 12 wherein said antigen capable of binding to antibodies to PAF is phosphorylcholine.

20 22. The kit of claim 12 wherein said antigen capable of binding to antibodies to PAF is phosphatidylcholine.

23. The kit of claim 12 wherein said antigen capable of binding to antibodies to PAF is lysophosphatidylcholine.